Therapeutic Targets for Traumatic Brain Injury
Georgetown University is seeking a licensing partner interested in thedevelopment of therapeutic treatments for traumatic brain injury (TBI).TBI is the leading cause of mortality and disability among youngindividuals in developed countries. Currently, there is no effectivetreatment for patients following TBI. The initial injury inducesbiochemical and cellular changes that contribute to continuing neuronaldamage and death over time. This continuing damage is known assecondary injury. Post mortem studies have shown that 30% of TBIfatalities have amyloid-beta deposits, which may occur less than 1 daypost injury. Georgetown researchers have shown in a recent NatureMedicine paper that blocking either beta- or gamma-secretase, proteinsresponsible for amyloid-beta production, can dramatically reduce motorand cognitive defects and reduce cell loss after experimental TBI.
美國
